NCT01944371View on ClinicalTrials.gov

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
HIVHuman Immunodeficiency Virus
Interventions
DRUG

Disulfiram

This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.

Trial Locations (2)

3004

Alfred Hospital, Melbourne

94110

San Francisco General Hospital, San Francisco

All Listed Sponsors
collaborator

Monash University

OTHER

collaborator

amfAR, The Foundation for AIDS Research

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of California, San Francisco

OTHER

NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study | Biotech Hunter | Biotech Hunter